Patients receiving nipocalimab plus standard of care improved by 4.7 points on the MG-ADL score, significantly more than placebo, and that was from baseline over weeks 22, 23, and 24, so around 6 ...

Eli Lilly launches 7.5 mg and 10 mg Zepbound vials for $499, also reducing prices for 2.5 mg and 5 mg vials. Self-pay patients can access Zepbound vials through LillyDirect, bypassing third-party ...

Nipocalimab demonstrates significant long-term efficacy and safety in generalized myasthenia gravis, improving MG-ADL scores and reducing immunoglobulin G levels. The phase 3 Vivacity-MG3 study ...

Nipocalimab binds FcRn with high specificity, reducing IgG levels while sparing innate and adaptive immune functions. Nipocalimab effectively reduced maternal alloantibodies implicated in fetal and ...

The primary role of FcRn is to extend the half-life of IgG due to its ability to bind, salvage, and recycle IgG in the circulation. Nipocalimab specifically targets the FcRn IgG binding site, thereby ...

Nipocalimab-treated patients saw a 4.7-point improvement from baseline in the myasthenia gravis - activities of daily living (MG-ADL) score in weeks 22, 23, and 24 - compared to a 3.25-point ...

In the new offering, Lilly is lowering the price of the 2.5-mg and 5-mg vials to $349 and $499 per month. It will also start selling 7.5-mg and 10-mg doses in vials at $599 and $699 a month.

SPRING HOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent publication in mAbs. The study showcases the drug’s high ...

Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the ...